Woodmont Investment Counsel LLC decreased its holdings in shares of Harvard Bioscience, Inc. (NASDAQ:HBIO) by 39.6% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 177,491 shares of the medical instruments supplier’s stock after selling 116,203 shares during the quarter. Woodmont Investment Counsel LLC owned approximately 0.51% of Harvard Bioscience worth $666,000 at the end of the most recent reporting period.

Other institutional investors have also made changes to their positions in the company. Northern Trust Corp lifted its holdings in Harvard Bioscience by 5.2% during the 2nd quarter. Northern Trust Corp now owns 86,205 shares of the medical instruments supplier’s stock valued at $220,000 after purchasing an additional 4,260 shares during the last quarter. New York State Common Retirement Fund acquired a new stake in Harvard Bioscience during the 3rd quarter valued at $321,000. Ameriprise Financial Inc. acquired a new stake in Harvard Bioscience during the 2nd quarter valued at $752,000. Essex Investment Management Co. LLC lifted its holdings in Harvard Bioscience by 38.7% during the 2nd quarter. Essex Investment Management Co. LLC now owns 429,460 shares of the medical instruments supplier’s stock valued at $1,095,000 after purchasing an additional 119,878 shares during the last quarter. Finally, Renaissance Technologies LLC lifted its holdings in Harvard Bioscience by 5.9% during the 1st quarter. Renaissance Technologies LLC now owns 560,500 shares of the medical instruments supplier’s stock valued at $1,457,000 after purchasing an additional 31,300 shares during the last quarter. 61.73% of the stock is owned by institutional investors and hedge funds.

Shares of Harvard Bioscience, Inc. (NASDAQ HBIO) opened at $3.30 on Wednesday. Harvard Bioscience, Inc. has a twelve month low of $2.25 and a twelve month high of $3.90. The company has a current ratio of 3.40, a quick ratio of 1.87 and a debt-to-equity ratio of 0.13. The firm has a market capitalization of $115.11, a price-to-earnings ratio of 110.00 and a beta of 1.01.

Harvard Bioscience (NASDAQ:HBIO) last posted its earnings results on Thursday, October 26th. The medical instruments supplier reported $0.03 earnings per share for the quarter, hitting the Zacks’ consensus estimate of $0.03. Harvard Bioscience had a positive return on equity of 1.11% and a negative net margin of 3.16%. The company had revenue of $25.05 million during the quarter, compared to the consensus estimate of $24.60 million. research analysts forecast that Harvard Bioscience, Inc. will post 0.05 EPS for the current fiscal year.

Separately, ValuEngine raised Harvard Bioscience from a “sell” rating to a “hold” rating in a report on Tuesday, August 1st.

TRADEMARK VIOLATION WARNING: “Woodmont Investment Counsel LLC Cuts Holdings in Harvard Bioscience, Inc. (HBIO)” was originally posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this piece on another publication, it was illegally copied and republished in violation of U.S. and international trademark & copyright law. The legal version of this piece can be viewed at https://www.thecerbatgem.com/2017/11/29/woodmont-investment-counsel-llc-cuts-holdings-in-harvard-bioscience-inc-hbio.html.

Harvard Bioscience Company Profile

Harvard Bioscience, Inc is a developer, manufacturer and marketer of a range of scientific instruments, systems and lab consumables used for basic research, drug discovery, clinical and environmental testing. The Company’s products are sold to thousands of researchers in over 100 countries through its global sales organization, Websites, catalogs and through distributors.

Institutional Ownership by Quarter for Harvard Bioscience (NASDAQ:HBIO)

Receive News & Stock Ratings for Harvard Bioscience Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Harvard Bioscience Inc. and related stocks with our FREE daily email newsletter.